217 Participants Needed

ARV-471 + Palbociclib for Breast Cancer

(mBC Trial)

Recruiting at 18 trial locations
JR
EB
AE
Overseen ByArvinas Estrogen Receptor, Inc.
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Arvinas Inc.
Must be taking: CDK4/6 inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called ARV-471 alone and with palbociclib in patients with advanced breast cancer who have tried other treatments. ARV-471 breaks down proteins that help cancer grow, and palbociclib stops cancer cells from multiplying.

Eligibility Criteria

This trial is for postmenopausal women with ER+/HER2- advanced breast cancer who've had prior hormonal therapy and chemotherapy. They must have measurable disease, be over 18, willing to undergo biopsies, and can't have more than two prior chemo regimens for advanced disease or symptomatic brain metastases.

Inclusion Criteria

I have been treated with hormone therapy for my advanced cancer for at least 6 months.
My cancer's size or presence can be measured by scans done within the last 28 days.
I have had 2 or fewer chemotherapy treatments for my advanced disease.
See 7 more

Exclusion Criteria

I haven't had radiation that affected more than 25% of my bone marrow or any in the last 4 weeks, except for pain relief.
I haven't taken any cancer treatment or experimental drugs in the last 14 days.
I have brain metastases but am stable and off high-dose steroids for 4 weeks.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive ARV-471 alone or in combination with palbociclib in 28-day cycles to assess safety, tolerability, and anti-tumor activity

up to 2 years
Monthly visits for dose administration and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Open-label extension (optional)

Participants may opt into continuation of treatment long-term

Long-term

Treatment Details

Interventions

  • ARV-471
  • Palbociclib (IBRANCE®)
Trial Overview The study tests ARV-471's safety and effectiveness alone and with palbociclib in treating breast cancer that has spread or cannot be cured by standard treatments. It involves increasing doses to find the right amount and then expanding the group to further assess its effects.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: ARV-471 and palbociclib (IBRANCE®)Experimental Treatment1 Intervention
Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days.
Group II: ARV-471Experimental Treatment1 Intervention
Parts A and B: ARV-471 administered QD or BID for 28 day cycles.

ARV-471 is already approved in United States for the following indications:

🇺🇸
Approved in United States as Vepdegestrant for:
  • None approved; under investigation for ER+/HER2- metastatic breast cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

Arvinas Inc.

Lead Sponsor

Trials
4
Recruited
730+

Arvinas Estrogen Receptor, Inc.

Lead Sponsor

Trials
19
Recruited
2,400+

Pfizer

Industry Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security